Wu Capital
Quan leads $80m Series A for China biotech player
Healthcare-focused VC firm Quan Capital has led an $80 million Series A round for Citrine Medicine, a Chinese biotech developer set up by Eight Roads, F-Prime Capital, and Vivo Capital.
Chinese AI-RPA start-up Laiye raises $42m Series C
Lightspeed China Partners and its global affiliate have co-led a $42 million Series C round for Laiye Technology, a Chinese artificial intelligence (AI) start-up that specializes in robotic process automation (RPA).
Chinese cancer database provider secures $140m
Medbanks, a Chinese oncology database platform, has raised around RMB1 billion ($140 million) in an extended Series D funding round led by Tencent Holdings and Wu Capital.
Cathay Innovation leads $35m round for China AI player Laiye
Cathay Innovation, the venture affiliate of Cathay Capital Private Equity, has led a $35 million extended Series B round of funding for Laiye Technology, a Chinese artificial technology (AI) start-up. Existing investors Lightspeed China and Wu Capital...
Wu Capital leads round for Chinese vocational training business
Sanjieke, a China-based vocational training services provider, has raised an RMB130 million ($19 million) in a Series B round of funding led by Wu Capital.